scholarly journals Assessment of tumor mutation burden calculation from gene panel sequencing data

2019 ◽  
Vol Volume 12 ◽  
pp. 3401-3409 ◽  
Author(s):  
Zhenwu Xu ◽  
Jiawei Dai ◽  
Dandan Wang ◽  
Hui Lu ◽  
Heng Dai ◽  
...  
Keyword(s):  
Gene Panel ◽  
Sequencing Data ◽  
Tumor Mutation Burden ◽  
Mutation Burden ◽  
Gene Panel Sequencing ◽  
Panel Sequencing

scholarly journals PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORS—THE MNP 2.0 STUDY

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii426-iii426
Author(s):  
Dominik Sturm ◽  
Felix Sahm ◽  
Felipe Andreiuolo ◽  
David Capper ◽  
Marco Gessi ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Gene Panel ◽  
Cns Tumors ◽  
Lower Grade ◽  
High Grade ◽  
Sequencing Data ◽  
Cns Tumor ◽  
Gene Panel Sequencing ◽  
Tumor Entities ◽  
Panel Sequencing

Abstract The large variety of CNS tumor entities affecting children and adolescents, some of which are exceedingly rare, results in very diverging patient outcomes and renders accurate diagnosis challenging. To assess the diagnostic utility of routine DNA methylation-based CNS tumor classification and gene panel sequencing, the Molecular Neuropathology 2.0 study prospectively integrated these (epi-)genetic analyses with reference neuropathological diagnostics as an international trial for newly-diagnosed pediatric patients. In a four-year period, 1,215 patients with sufficient tissue were enrolled from 65 centers, receiving a reference neuropathological diagnosis according to the WHO classification in >97%. Using 10 FFPE sections as input, DNA methylation analysis was successfully performed in 95% of cases, of which 78% with sufficient tumor cell content were assigned to a distinct epigenetic tumor class. The remaining 22% did not match any of 82 represented classes, indicating novel rare tumor entities. Targeted gene panel sequencing of >130 genes performed for 96% of patients with matched blood samples detected diagnostically, prognostically, or therapeutically relevant somatic alterations in 48%. Germline DNA sequencing data indicated potential predisposition syndromes in ~10% of patients. Discrepant results by neuropathological and epigenetic classification (29%) were enriched in histological high-grade gliomas and implicated clinical relevance in 5% of all cases. Clinical follow-up suggests improved survival for some patients with high-grade glioma histology and lower-grade molecular profiles. Routine (epi-)genetic profiling at the time of primary diagnosis adds a valuable layer of information to neuropathological diagnostics and will improve clinical management of CNS tumors.

scholarly journals A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single-Nucleotide Variant Detection

2017 ◽  
Vol 19 (5) ◽  
pp. 651-658 ◽  
Author(s):  
Chung Lee ◽  
Joon S. Bae ◽  
Gyu H. Ryu ◽  
Nayoung K.D. Kim ◽  
Donghyun Park ◽  
...  
Keyword(s):  
Single Nucleotide Variant ◽  
Gene Panel ◽  
Sequencing Data ◽  
Single Nucleotide ◽  
Variant Detection ◽  
Gene Panel Sequencing ◽  
Panel Sequencing

Comprehensive genomic profiling to merge precision medicine with immunotherapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e23108-e23108
Author(s):  
Stephen Lyle ◽  
Julie Y Tse ◽  
Ruobai Sun ◽  
Xiu Huang ◽  
Meaghan Russell ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Copy Number ◽  
Treatment Strategies ◽  
Gene Panel ◽  
Next Generation Sequencing Data ◽  
Patient Treatment ◽  
Clinical Samples ◽  
Sequencing Data ◽  
Tumor Mutation Burden ◽  
Mutation Burden

e23108 Background: Immunotherapy is rapidly emerging as one of the most promising therapeutic options in clinical oncology. However, not all patients will respond to immune-oncology drugs and diagnostic assays are urgently needed to identify biomarkers that predict response to these therapies. We developed an assay that utilizes next generation sequencing data to simultaneously determine different types of somatic changes in tumors. The assay was designed, in part, to facilitate identification of cancer patients most likely to respond to immunotherapies by detecting 1) CD274 (PD-L1) copy number alterations, 2) viral infections (HPV16/18 and EBV), 3) microsatellite instability (MSI), and 4) tumor mutation burden. Methods: We developed a 435-gene panel assay (CancerPlex) with the goal of identifying all the genomic changes that inform treatment decisions with the highest possible accuracy. We thoroughly evaluated the performance of the assay using reference samples that represent all classes of genetic variation, including SNPs, indels, copy number changes, rearrangements, HPV/EBV infection and MSI. FFPE clinical samples were also evaluated to assess the ability of the assay to detect genetic variation in complex, heterogeneous tumors. Results: The assay has excellent performance, with a mean sensitivity of 99.4% and specificity of 99.9% for detecting somatic mutations with an allele fraction as low as 10%. The assay identified the MSI status of colorectal tumors with the same sensitivity as immunohistochemistry but with greater sensitivity than PCR. We also showed that calculating tumor mutation burden using the 435-gene panel predicts response to pembrolizumab as effectively as using whole exome sequencing. Among 892 patients across all tumor types, 6.8% were identified as candidates for immunotherapy based upon high tumor mutation burden and/or MSI status. Conclusions: The capacity of the 435-gene panel to determine all of the critical genetic changes, tumor mutation burden, MSI status, CD274 (PD-L1) CNVs, and HPV/EBV status has important ramifications for patient treatment strategies, including identification of patients who are more likely to benefit from immune checkpoint inhibitor therapies.

scholarly journals Matrilineal analysis of mutations in the DMD gene in a multigenerational South Indian cohort using DMD gene panel sequencing

2021 ◽  
Author(s):  
Arun Shastry ◽  
Sankaramoorthy Aravind ◽  
Meeta Sunil ◽  
Keerthi Ramesh ◽  
Berty Ashley ◽  
...  
Keyword(s):  
Gene Panel ◽  
South Indian ◽  
Dmd Gene ◽  
Gene Panel Sequencing ◽  
Panel Sequencing

scholarly journals Characterization of intellectual disability and autism comorbidity through gene panel sequencing

2019 ◽  
Vol 40 (9) ◽  
pp. 1346-1363 ◽  
Author(s):  
Maria C. Aspromonte ◽  
Mariagrazia Bellini ◽  
Alessandra Gasparini ◽  
Marco Carraro ◽  
Elisa Bettella ◽  
...  
Keyword(s):  
Intellectual Disability ◽  
Gene Panel ◽  
Gene Panel Sequencing ◽  
Panel Sequencing

scholarly journals Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk

2015 ◽  
Vol 372 (23) ◽  
pp. 2243-2257 ◽  
Author(s):  
Douglas F. Easton ◽  
Paul D.P. Pharoah ◽  
Antonis C. Antoniou ◽  
Marc Tischkowitz ◽  
Sean V. Tavtigian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Gene Panel ◽  
Gene Panel Sequencing ◽  
Panel Sequencing
Sign in / Sign up

Export Citation Format

Share Document